Barclays raised the firm’s price target on Edwards Lifesciences (EW) to $103 from $99 and keeps an Overweight rating on the shares. The firm says the company’s pipeline update and long-term plan reinforce its “commitment to growth, innovation and therapeutic development.” The analyst sees Edwards’ clinical- and pipeline-related catalysts to continue to drive durable growth and shareholder returns.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $100 from $95 at RBC Capital
- Edwards Lifesciences price target raised to $92 from $90 at Truist
- Edwards Lifesciences price target raised to $92 from $90 at UBS
- Cautious Optimism for Edwards Lifesciences: Hold Rating Maintained Amid Back-End-Loaded Growth Expectations
- Edwards Lifesciences price target raised to $88 from $83 at Baird